Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:1/28/2008

VIENNA, Va., Jan. 28 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI CORPORATION (Amex: CVM) to its shareholders:

Dear Fellow Shareholders:

Our Company underwent a wonderful transformation last year from an intermediate stage company in its development to a late-stage biotechnology company. We are now one of a very select number of companies that have a completely novel medicine with blockbuster potential ready to go into a Phase III clinical trial. Our position is further enhanced by the fact that we are well capitalized and that we are building our own manufacturing facility close to Baltimore, Maryland. This facility will be capable of producing between $500 million and $600 million worth of Multikine(R) cancer drug per year, with the ability to triple production within about one year. The construction of the facility is scheduled for completion in the 3rd quarter of 2008.

Company highlights of 2007:

-- FDA clearance of Multikine for Phase III clinical trial in head and

neck cancer

-- Raised U.S. $15 million

-- Multikine granted Orphan drug designation in U.S.

-- Started build-out of manufacturing facility for Multikine to support

upcoming Phase III study and commercial sale

-- Started planning and pricing of our global clinical trial designed to

lead to marketing approval for Multikine

We expect 2008 to be another very positive year. We plan to contract with one or more Clinical Research Organizations to run our 800 patient Multikine Phase III trial which we expect to start in the last quarter of 2008. It will be run as an open label study (a study in which it is apparent which patients receive Multikine versus those who do not). The open label design will give us the opportunity to get early indications of how successful our study will be.

We look forward to moving into the new facility later this year and we anxiously await the first indications from the open-label Phase III clinical trial with Multikine in advanced primary (not yet treated) head and neck cancer, representing a large unmet medical need and a disease in dire need of new and non-toxic treatments.

Thank you for your continued support. We invite you to visit our new website at http://www.cel-sci.com to learn more about our breakthrough work in empowering immune defenses to defeat cancer.

Sincerely yours,

Geert Kersten Maximilian de Clara

Chief Executive Officer President

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2007. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
2. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
3. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
4. Brooke Franchise Corporation Announces Selected July Results
5. MedThink Communications Retained by NanoBio Corporation
6. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
7. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
8. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
9. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
10. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
11. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp ... in and around the greater Phoenix metropolitan region, is announcing a charity event ... mission of the Homeless Youth Connection is to promote community awareness of the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, ... residential and commercial clients in the northern Alabama and Georgia regions, is embarking ... Since 1977, Nobis Works has built a network of support and education facilities ...
(Date:12/7/2016)... ... December 07, 2016 , ... Students attending Envision’s ... unique opportunity to get hands-on experience in an emergency medical simulation, When Care ... to gain invaluable, real-life medical skills that are critical success in a future ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... the drug in their bodies, a researcher at the Icahn School of Medicine ... Research. , The study found that when young children are exposed to secondhand ...
(Date:12/7/2016)... PHILADELPHIA, PA (PRWEB) , ... December 07, 2016 ... ... story of a women growing up with a schizophrenic mother in a unique, ... social worker who specializes in treating trauma and addictive disorders at her private ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. ... health care products and services to office-based dental, animal health ... percent equity investment in Marrodent, one of Poland,s ... approximately $32 million. This transaction was announced on August 30, ... in Poland since 2014, and Marrodent ...
(Date:12/8/2016)... Research and Markets has announced the addition of ... their offering. ... The report provides separate comprehensive analytics for the ... Rest of World. Annual estimates and forecasts are provided ... provided for these markets. Market data and analytics are derived from primary ...
(Date:12/7/2016)... , Dec. 7, 2016 "Lantus (Insulin Glargine) Biosimilar Clinical ... on 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 ... , Japan , Kenya , ... Germany , China , Slovakia ... 1 & 2 diabetes mellitus. The patent on Lantus expired in 2014. ...
Breaking Medicine Technology: